Experimental lymphoma drug IPH6501 tested in early trial – but study halted

NCT ID NCT06088654

Terminated Disease control Sponsor: Innate Pharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. The study was terminated early, so results are limited and it is unclear if the drug will move forward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPH6501 (an experimental drug that targets CD20 on cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with certain types of Non-Hodgkin lymphoma that have not responded to other therapies.
What could go wrong: This is a very early (first-in-human) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Austin Health

Heidelberg, Australia
Cedars Sinai

Los Angeles, California, 90048, United States
Centre Hospitalier Regional Universitaire de Lille

Lille, France
Centre Hospitalier Universitaire de Nantes

Nantes, France
City of Hope

Duarte, California, 91010, United States
Hospices Civils de Lyon

Lyon, 69002, France
Hôpital de la Coception

Marseille, 13005, France
Icahn School Of Medicine At Mount Sinai

New York, New York, 10029, United States
Institute Bergonie

Bordeaux, France
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Monash Health

Clayton, Victoria, 3168, Australia
Peninsula Private Hospital

Frankston, Victoria, 3910, Australia
Siteman Cancer Center

St Louis, Missouri, 63110, United States
Wollongong Private Hospital

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.